Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PGEN
stocks logo

PGEN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
8.29M
+596.27%
-0.084
+68.04%
21.20M
+1480.91%
-0.075
-58.33%
27.00M
+3054.21%
-0.055
-38.89%
Estimates Revision
The market is revising Upward the revenue expectations for Precigen, Inc. (PGEN) for FY2025, with the revenue forecasts being adjusted by 0.09% over the past three months. During the same period, the stock price has changed by -2.64%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.09%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+121.27%
In Past 3 Month
Stock Price
Go Down
down Image
-2.64%
In Past 3 Month
Wall Street analysts forecast PGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PGEN is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast PGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PGEN is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.690
sliders
Low
9.00
Averages
9.00
High
9.00
Current: 3.690
sliders
Low
9.00
Averages
9.00
High
9.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$9
2025-11-14
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$9
2025-11-14
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Precigen to $9 from $8.50 and keeps a Buy rating on the shares post the Q3 report. The firm says the Papzimeos launch is generating a "robust" pipeline of patients.
Citizens JMP
Outperform
maintain
$6 -> $8
2025-08-19
Reason
Citizens JMP
Price Target
$6 -> $8
2025-08-19
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Precigen to $8 from $6 and keeps an Outperform rating on the shares. Precigen discussed the approval of PAPZIMEOS for the treatment of respiratory papillomatosis, as well as the price, with a wholesale acquisition cost of $460k per patient, higher than the firm's prior assumption of $200k per patient, the analyst tells investors in a research note.
JPMorgan
Underweight -> Neutral
upgrade
$NULL
2025-08-15
Reason
JPMorgan
Price Target
$NULL
2025-08-15
upgrade
Underweight -> Neutral
Reason
JPMorgan upgraded Precigen to Neutral from Underweight without a price target following the FDA's approval of Papzimeos. The firm cites the removal of Precigen's "major regulatory overhang" and its revenue potential for the upgrade. However, the adoption of Papzimeos will take time to materialize, the analyst tells investors in a research note. JPMorgan believes that with limited cash on the balance sheet to support the launch, further dilution post approval is "likely inevitable" for Precigen.
H.C. Wainwright
H.C. Wainwright
Buy
upgrade
$6
2025-08-15
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$6
2025-08-15
upgrade
Buy
Reason
H.C. Wainwright raised the firm's price target on Precigen to $8.50 from $6 and keeps a Buy rating on the shares following FDA approval of Papzimeos for the treatment of recurrent respiratory papillomatosis. The firm did not expect an approval to come nearly two weeks earlier than the action date of August 27. The FDA's "unprecedented way" of providing full approval without a need for a randomized study underscores the unmet need in RPR, the analyst tells investors in a research note. H.C. Wainwright expects the drug to generate sales of $1.1B in 2033 from $138M in 2026.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$6
2025-03-20
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$6
2025-03-20
Reiterates
Strong Buy
Reason
Citizens Capital Markets
Jason Butler
Buy
Reiterates
$6
2025-03-20
Reason
Citizens Capital Markets
Jason Butler
Price Target
$6
2025-03-20
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Precigen Inc (PGEN.O) is -15.17, compared to its 5-year average forward P/E of -6.08. For a more detailed relative valuation and DCF analysis to assess Precigen Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.08
Current PE
-15.17
Overvalued PE
1.35
Undervalued PE
-13.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.89
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.43
Undervalued EV/EBITDA
-5.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
34.39
Current PS
0.00
Overvalued PS
67.81
Undervalued PS
0.97
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 801.59% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

PGEN News & Events

Events Timeline

(ET)
2025-11-13
16:25:40
Precigen Announces Q3 Earnings Per Share of $1.06 Compared to a Loss of 9 Cents Last Year
select
2025-10-13 (ET)
2025-10-13
07:02:36
Precigen showcases long-term findings indicating sustained responses to PAPZIMEOS
select
2025-08-15 (ET)
2025-08-15
08:59:49
Video: UnitedHealth jumps after Berkshire buy, Target slips after downgrade
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-09Businesswire
Promega Collaborates with Oxford to Accelerate Precision Medicine Research
  • Technological Breakthrough: Promega's collaboration with SUNY Stony Brook and the University of Oxford utilizes NanoBRET® technology to characterize inhibitors targeting cancer cells directly in live cells, revealing the connection between drug efficacy and tumor metabolic state, thus advancing precision oncology.
  • Target Discovery: The study focuses on the PRMT5 protein, identifying a key vulnerability in approximately 10-15% of cancers where MTAP gene deletion alters PRMT5's interaction, potentially offering new strategies for cancer treatment.
  • Biosensor Application: The CBH-002 probe developed by Oxford can measure PRMT5 inhibitor activity in live cells, demonstrating how MTA influences drug selectivity, paving the way for highly targeted therapies for MTAP-deleted cancers.
  • Collaboration Between Academia and Industry: This research underscores the value of academic-industry partnerships, combining expertise in chemical biology and assay design to drive the development of future precision medicines, which holds significant strategic implications.
[object Object]
Preview
4.0
11-15NASDAQ.COM
HC Wainwright & Co. Reaffirms Buy Rating for Precigen (PGEN)

  • Analyst Recommendation: HC Wainwright & Co. maintains a Buy recommendation for Precigen (NasdaqGS:PGEN), with a projected one-year price target of $8.42/share, indicating a potential upside of 73.68% from its current price of $4.84/share.

  • Revenue and Earnings Projections: Precigen's projected annual revenue is expected to reach $59 million, reflecting an increase of 829.62%, with a projected non-GAAP EPS of 0.20.

  • Institutional Ownership Trends: There has been an increase in institutional ownership of Precigen, with 277 funds reporting positions, a rise of 8.63% in the last quarter, and total shares owned increasing by 28.21% to 133,539K shares.

  • Shareholder Activity: Notable changes in shareholder positions include Patient Capital Management increasing its stake by 38.52%, while LMORX - Patient Opportunity Trust Class R reduced its holdings by 6.25%.

[object Object]
Preview
8.0
11-14NASDAQ.COM
Purchase Precigen at $3.50 and Achieve 27.1% Returns Through Options

  • Put Selling Mechanics: Selling a put option does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, which occurs if the stock price drops significantly.

  • Counterparty Risk and Returns: The put seller's only benefit is the premium collected, which offers a 12.4% annualized return unless the stock declines enough to trigger the exercise of the option.

  • Volatility and Analysis: The historical volatility of Precigen Inc is calculated at 104%, which, along with fundamental analysis, can help assess the risk-reward balance of selling the January 2028 put option at a $3.50 strike price.

  • Market Context: The article emphasizes the importance of understanding options trading dynamics and the specific market conditions surrounding Precigen Inc's stock performance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Precigen Inc (PGEN) stock price today?

The current price of PGEN is 3.69 USD — it has increased 1.93 % in the last trading day.

arrow icon

What is Precigen Inc (PGEN)'s business?

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

arrow icon

What is the price predicton of PGEN Stock?

Wall Street analysts forecast PGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PGEN is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Precigen Inc (PGEN)'s revenue for the last quarter?

Precigen Inc revenue for the last quarter amounts to 2.92M USD, increased 206.61 % YoY.

arrow icon

What is Precigen Inc (PGEN)'s earnings per share (EPS) for the last quarter?

Precigen Inc. EPS for the last quarter amounts to -1.06 USD, increased 1077.78 % YoY.

arrow icon

What changes have occurred in the market's expectations for Precigen Inc (PGEN)'s fundamentals?

The market is revising Upward the revenue expectations for Precigen, Inc. (PGEN) for FY2025, with the revenue forecasts being adjusted by 0.09% over the past three months. During the same period, the stock price has changed by -2.64%.
arrow icon

How many employees does Precigen Inc (PGEN). have?

Precigen Inc (PGEN) has 143 emplpoyees as of December 13 2025.

arrow icon

What is Precigen Inc (PGEN) market cap?

Today PGEN has the market capitalization of 1.28B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free